Nascent Biotech, Inc. (OTCMKTS:NBIO – Get Free Report)’s share price passed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $0.06 and traded as low as $0.05. Nascent Biotech shares last traded at $0.05, with a volume of 94,600 shares changing hands.
Nascent Biotech Trading Up 0.2 %
The company’s fifty day simple moving average is $0.06 and its 200 day simple moving average is $0.06.
Nascent Biotech Company Profile
Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.
Featured Stories
- Five stocks we like better than Nascent Biotech
- How to Invest in Insurance Companies: A Guide
- Insiders Are Selling, But These 3 Stocks Are Must-Buys
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Rivian Defies Doubters: Delivery Triumph Fuels Stock Surge
- Profitably Trade Stocks at 52-Week Highs
- Hindenburg Short Report Slams Carvana Over Alleged ‘Grift’
Receive News & Ratings for Nascent Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nascent Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
